ELMOD1: A Potential Drug Target and Biomarker for Diseases (G55531)

Target Name: ELMOD1

NCBI ID: G55531

ELMOD1

ELMOD1: A Potential Drug Target and Biomarker for Diseases

ELMOD1 (Endoplasmic Reticulum-Associated Protein 1) is a protein that is expressed in most tissues and cells of the body. It is a member of the family of transmembrane proteins, which means that it spans the cell membrane and extends into the cytoplasm. ELMOD1 is involved in various cellular processes, including cell signaling, protein folding, and the regulation of intracellular signaling pathways.

ELMOD1 has also been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

ELMOD1 is involved in several cellular signaling pathways that are critical for the development and progression of various diseases. One of the most well-studied functions of ELMOD1 is its role in the regulation of the Notch signaling pathway. Notch signaling is a critical pathway that regulates cell-to-cell communication and plays a role in the development of various diseases, including cancer.

ELMOD1 has been shown to be a negative regulator of the Notch signaling pathway. This means that when Notch signaling is activated, ELMOD1 is recuppressed, and when Notch signaling is inhibited, ELMOD1 is expressed. This regulation of Notch signaling by ELMOD1 has important implications for the development and progression of various diseases.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, ELMOD1 has been shown to be involved in the regulation of neurotransmitter homeostasis. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these diseases.

ELMOD1 has also been shown to be involved in the regulation of cell apoptosis, which is a natural process that helps maintain tissue homeostasis and removes damaged or dysfunctional cells. In neurodegenerative diseases, misregulated apoptosis can contribute to the development and progression of these diseases.

In cancer, ELMOD1 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in tumors. This is thought to contribute to the development and progression of cancer.

ELMOD1 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been shown to be associated with the development and progression of these diseases, making it an attractive target for researchers to study and develop new treatments.

In conclusion, ELMOD1 is a protein that is involved in various cellular signaling pathways that are critical for the development and progression of diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of ELMOD1 in disease and to develop new treatments.

Protein Name: ELMO Domain Containing 1

Functions: Acts as a GTPase-activating protein (GAP) toward guanine nucleotide exchange factors like ARL2, ARL3, ARF1 and ARF6, but not for GTPases outside the Arf family

The "ELMOD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELMOD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets